Western blotting of PD-L1 mAbs.

Slides:

Advertisements

Similar presentations

Pirh2 promotes p73 ubiquitination in vivo.

Advertisements

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Supplementary Figure 2. AKT1 AKT1 AKT2 pAKT ERK pERK A1847 A2780 CaOV3

The absence of ADCC by nivolumab in vitro.

Identification of novel IgGs in alpaca serum.

Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.

Overexpression of BTAK/Aurora-A in ovarian carcinoma.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

Thiocolchicoside inhibits TNF-dependent IκBα phosphorylation, IκBα degradation, p65 phosphorylation, and p65 nuclear translocation. Thiocolchicoside inhibits.

Characterisation of eSRS21 protein using an anti-eSRS21 antibody.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

Cathepsin D in wild-type and Nuc1 RPE

A: Representative Western blot showing a band migrating at ∼90 kDa corresponding to neprilysin protein. A: Representative Western blot showing a band migrating.

CML-HSA treatment activates MAPK family members ERK1/2 and p38 but not JNK. Samples were taken at the indicated times after 100 μg/ml CML-HSA exposure.

Streptavidin identified in the vaccine protein profiles.

co-IP of LEDGF/p75 and MeCP2.

Quantification of NMT knockdown.

Recognition of naturally processed HTLV-1 Tax protein derived from HAM patient's PBMC. A, HTLV-1 Tax protein content was evaluated by Western blot analysis.

FOXO3a phosphorylation and expression.

CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.

EGCG inhibits cell survival and growth of EFT cell lines but not of HBMECs. A, dose-responsive curves of fractional survival of EFT cells (TC32 and TC71)

B7-1 and PD-1 compete for binding to PD-L1.

BME treatment increases granzyme B expression in NK 3.3 cells.

ALDH1A3 is mainly responsible for the ALDH activity in two human cholangiocarcinoma lines. ALDH1A3 is mainly responsible for the ALDH activity in two human.

Geldanamycin-induced endocytosis and down-regulation of ErbB2 in cells expressing ErbB2 only. Geldanamycin-induced endocytosis and down-regulation of ErbB2.

CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection of CXCR4 siRNAs. CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection.

Anti-Flk-1 mAb treatment reduces vessel density in tumors.

MiR-200c is a PI3K–AKT signaling pathway regulator in CRC

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

Expression pattern of TLR-4 and MyD88 in EOC cells.

Characterization of the complex formed at the Fra-1 RCE1.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs on tumor cells. Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

PKCζ is tyrosine phosphorylated by EGF and contributes to EGF-induced activation of ERK in Mef cells. PKCζ is tyrosine phosphorylated by EGF and contributes.

SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression. SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression.

IGF-II antibodies inhibited IGF-II-induced phosphorylation of IGF-IR and insulin receptor (IR) in the breast cancer MCF-7 cells. IGF-II antibodies inhibited.

Expression of B7-H1, B7-DC, and PD-1 on B cells.

PD-1 expression in ovarian cancer.

Characterization of DNA-PK and PARP-1 levels and activities in the cell lines studied. Characterization of DNA-PK and PARP-1 levels and activities in the.

Identification of the recombinant structural proteins expressed in recombinant baculovirus-infected Sf9 cells by immunofluorescence assay with rabbit anti-FMDV.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Characterization of monoclonal antibody 4

The Ser124 site of Cdc25A is required for Cdc25A degradation in response to I3C induction. The Ser124 site of Cdc25A is required for Cdc25A degradation.

The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

AS1411 alters subcellular distribution of PRMT5 in a time-dependent, dose-dependent, and nucleolin-dependent manner. AS1411 alters subcellular distribution.

SAHA blocks IR-induced increase of RAD51 protein in MM cells.

Amino acid residues in the PD-L1 IgV domain involved in PD-1 and/or B7-1 binding. Amino acid residues in the PD-L1 IgV domain involved in PD-1 and/or B7-1.

Effect of bevacizumab on the proliferation of A2780 cells.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Induction of PARP cleavage (A) and activation of caspases (B) after treatment with a combination of TRAIL and cisplatin. Induction of PARP cleavage (A)

PARP1 suppresses the transcription of PD-L1 in cancer cells.

RA-9 induces G2–M cell-cycle arrest and caspase-mediated apoptosis in ovarian cancer cells. RA-9 induces G2–M cell-cycle arrest and caspase-mediated apoptosis.

In the presence of human monocytes, estradiol increased breast cancer cell dissemination to the periphery via CCL2 and CCL5. In the presence of human monocytes,

Effect of dexamethasone on PCDGF/GP88 mRNA and protein expressions and effect of PCDGF/GP88 on dexamethasone-induced cell death. Effect of dexamethasone.

CPGL is a growth suppressor in pancreatic cancer cell lines.

LY elicits hyperphosphorylation of Akt.

Detection of protein levels of Cdc25AWT and its mutation derivatives in breast cancer cells with I3C treatment. Detection of protein levels of Cdc25AWT.

Ex vivo profiling of PD-1 blockade using MDOTS

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Depletion of murine Dnmt proteins after 5-Aza-CdR treatment.

I3C reduces the level of Cdc25A protein in breast cancer cells.

Comparison of PD-L1 mAbs in IHC across multiple tumor types.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Time course of NMT knockdown.

Presentation transcript:

Western blotting of PD-L1 mAbs. Western blotting of PD-L1 mAbs. A, multichannel Western blot analysis with dose curve of each antibody (5, 1.25, 0.31, and 0.078 μg/mL per lane) on HDLM2, Caki-2, or SKBR3, as indicated. Blot was developed with an equal mixture of anti-mouse and anti-rabbit IgG-HRP antibodies. B, Western blot analysis of hematologic (HDLM2, L428, and OC1-LY1), kidney (Caki-2, UMRC-6, 769C, and SN12C), ovarian (36M2, A2780-C70, and OVCAR3), and breast cancer cell lines (MDA231, SKBR3, and BT474) with anti–PD-L1 mAbs: 5A4 (10 μg/mL), 7G11 (20 μg/mL), 9A11 (5μg/mL), or anti–β-actin A and B are representative of two to five experiments. Kathleen M. Mahoney et al. Cancer Immunol Res 2015;3:1308-1315 ©2015 by American Association for Cancer Research